NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

A. Wainberg, Zev; Melisi, Davide; Macarulla, Teresa; Pazo-Cid, Roberto; R Chandana, Sreenivasa; de la Fouchardière, Christelle; Dean, Andrew; Kišš, Igor; Jin Lee, Woo; Oliver Goetze, Thorsten; Van Cutsem, Eric; Scott Paulson, Andrew; Bekaii‐Saab, Tanios; Pant, Shubham; Hubner, Richard; Xiao, Zhimin; Chen, Huanyu; Benzaghou, Fawzi; M. O’Reilly, Eileen

doi:10.1016/s0140-6736(23)01366-1

Public

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Published in The Lancet • Sep 11, 2023

Authors:

Zev A. Wainberg

Davide Melisi

Teresa Macarulla

Abstract

Background Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC). Met...

Subject

Medicine

Gemcitabine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!